University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Felix Y. Feng, MD

Felix Y. Feng, MD

Associate Professor of Radiation Oncology, Depts. of Urology and Medicine; Vice Chair for Faculty Development and Director of Translational Research, Department of Radiation Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

I am a physician-scientist focused on clinical and translational research aimed at improving outcomes for patients with prostate cancer. My research interests include 1) the discovery of prognostic/predictive biomarkers in prostate cancer and 2) the development of rational approaches of targeted treatment for therapy-resistant disease. My laboratory focuses on sequencing and microarray-based approaches to identify molecular determinants of response from samples from prostate cancer patients treated on clinical trials. In addition, I am co-principal investigator of one of the first biomarker-driven clinical trials for patients with metastatic prostate cancer (NCI 9012; NCT01576172) and oversee a clinic focused on prostate cancer patients.


Stanford University, B.S., 06/1998, Biological Studies
Washington University School of Medicine, M.D., 06/2002, Medicine

Professional Experience

  • 2002-2003
    Intern, Dept of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor MI
  • 2003-2005
    Resident, Dept of Radiology, University of Michigan Medical Center, Ann Arbor, MI
  • 2005-2006
    Post-Doctoral Research Fellow, Dept of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
  • 2006-2010
    Resident, Dept of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
  • 2009-2010
    Chief Resident, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2010-2016
    Assistant Professor, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2010-2012
    Assistant Professor, Dept of Radiation Oncology, Ann Arbor Veteran's Health System, Ann Arbor, MI
  • 2010-present
    Leader, the Genitourinary Cancer Translational Research Program for the NRG/RTOG Cooperative Group
  • 2011
    Acting Chief, Radiation Oncology, Dept of Radiation Oncology, Ann Arbor Veteran's Health System, Ann Arbor, MI
  • 2013-2016
    Director, Division of Translational Genomics, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2015-2016
    Associate Chair for Laboratory Research, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2016-present
    Associate Professor of Radiation Oncology, Urology, and Medicine
  • 2016-present
    Vice Chair for Faculty Development and Translational Research, Dept of Radiation Oncology, University of California at San Francisco, CA

Honors & Awards

  • 1997
    Barry M. Goldwater Fellowship for Excellence in Mathematics, Science, and Engineering
  • 1998-2002
    Dr. Philip Majerus Distinguished Alumni Scholarship
  • 2002
    Dr. Richard S. Brookings Medical School Prize
  • 2008
    American Society of Therapeutic Radiology and Oncology Resident Clinical Research Award
  • 2010
    Radiological Society of North America Roentgen Resident/Fellow Research Award
  • 2012
    American Society of Radiation Oncology Basic Science Award
  • 2014
    Radiobiology Teacher of the Year, Dept of Radiation Oncology, University of Michigan
  • 2016
    American Society of Radiation Oncology Clinical Science Award

Selected Publications

  1. Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Res. 2017 Sep 15.
    View on PubMed
  2. Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res. 2017 Sep 12.
    View on PubMed
  3. Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, Jan YJ, Zhu YZ, Cheng S, Feng FY, Chen P, Hou S, Agopian V, Hsiao YS, Tseng HR, Posadas EM, Yu HH. Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. Adv Healthc Mater. 2017 Sep 11.
    View on PubMed
  4. Cai H, Zhang T, Zhao M, Mao J, Cai C, Feng F. Co-expression of lipase isozymes for enhanced expression in Pichia pastoris. Lett Appl Microbiol. 2017 Oct; 65(4):335-342.
    View on PubMed
  5. Gan L, Liu Z, Feng F, Wu T, Luo D, Hu C, Sun C. Foxc2 coordinates inflammation and browning of white adipose by leptin-STAT3-PRDM16 signal in mice. Int J Obes (Lond). 2017 Aug 23.
    View on PubMed
  6. Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. NPJ Breast Cancer. 2017; 3:29.
    View on PubMed
  7. Lin JH, Feng F, Yu MC, Wang CH, Chang PC. Modulation of periodontitis progression using pH-responsive nanosphere encapsulating metronidazole or N-phenacylthialzolium bromide. J Periodontal Res. 2017 Aug 10.
    View on PubMed
  8. Jia P, Bao L, Chen H, Yuan J, Liu W, Feng F, Li J, Tang H. Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies. Osteoporos Int. 2017 Aug 09.
    View on PubMed
  9. Green M, Feng FY, Mehra R, Spratt DE. Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. Immunotherapy. 2017 Aug; 9(9):695-699.
    View on PubMed
  10. Son CH, Hamstra DA, Feng FY, Liauw SL. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352.
    View on PubMed
  11. Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV. Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. Cancer Res. 2017 Sep 15; 77(18):4745-4754.
    View on PubMed
  12. Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, Spratt DE. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2017 Jul 15.
    View on PubMed
  13. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2017 Jul 14.
    View on PubMed
  14. Dess RT, Morgan TM, Nguyen PL, Mehra R, Sandler HM, Feng FY, Spratt DE. Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. Curr Urol Rep. 2017 Jul; 18(7):55.
    View on PubMed
  15. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017 Jun 24.
    View on PubMed
  16. Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2017 Jun 17.
    View on PubMed
  17. Aggarwal RR, Feng FY, Small EJ. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74.
    View on PubMed
  18. Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, Cotter MB, Bowden M, Lis RT, Zhao SG, Wu Q, Feng FY, Loda M, He HH, Liu XS, Brown M. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci U S A. 2017 Jun 27; 114(26):E5207-E5215.
    View on PubMed
  19. Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 2017 Jun 06; 19(10):2045-2059.
    View on PubMed
  20. Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 Sep; 35(9):542.e25-542.e32.
    View on PubMed

Go to UCSF Profiles, powered by CTSI